文献速递肾移植

抢先使用艾尔巴韦与格拉瑞韦治疗HCV病毒血症供肾移植至未感染受者的试验

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.
PubMed 文献 · Kidney Int Rep · 2020-01-13

该先导临床试验将HCV感染供者的肾脏移植给HCV未感染受者,术后抢先使用艾尔巴韦与格拉瑞韦12周。8例受者中无人移植后2周以上可检测到HCV病毒血症,全部获得治疗后12周持续病毒学应答,无研究相关严重不良事件。

要点

  • HCV病毒血症供肾移植给未感染受者后抢先使用艾尔巴韦与格拉瑞韦可清除HCV感染。
  • 8例受者均获得SVR12,移植后2周以上未检测到HCV病毒血症。
  • 无研究相关严重不良事件,1例因静脉血栓形成发生早期移植物丢失。

核心结论

  • 抢先使用艾尔巴韦与格拉瑞韦可在接受HCV感染供肾的HCV未感染受者中清除HCV感染。

研究设计与样本

  • 先导临床试验,2017年8月至2019年3月共筛查33例,8例接受HCV病毒血症供肾移植并抢先使用艾尔巴韦与格拉瑞韦12周。

主要发现

  • 8例受者移植后2周以上均无可检测HCV病毒血症,全部获得SVR12。
  • 无研究相关严重不良事件;1例因静脉血栓形成发生早期移植物丢失,其余7例6个月时移植物功能良好。
  • 供者肾脏供者概况指数中位数31%(范围29%-65%),受者等待移植中位时间6.5个月(范围1-19个月)。

临床怎么用

  • 对于HCV病毒血症供肾移植给HCV未感染受者,可考虑术后抢先使用艾尔巴韦与格拉瑞韦12周以预防HCV感染。

局限性

  • 本研究为先导临床试验,样本量小(8例接受移植),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Long wait times for kidney transplants have prompted investigation into strategies to decrease the discarding of potentially viable organs. Recent reports suggest that kidneys from hepatitis C virus (HCV)-infected donors may be transplanted into HCV-naive donors followed by direct-acting antiviral therapy. METHODS: This was a pilot clinical trial to transplant kidneys from HCV-infected donors into HCV-naive recipients with preemptive use of elbasvir and grazoprevir for 12 weeks. The primary outcome was sustained virologic response 12 weeks after completion of therapy. Secondary outcomes were safety, quality of life, and early viral kinetics. RESULTS: A total of 33 patients were screened, and 8 underwent kidney transplantation from a HCV-viremic donors from August 2017 to March 2019. The median donor kidney donor profile index was 31% (range, 29%-65%), and patients who underwent transplantation waited a median of 6.5 months (range, 1-19 months). None had detectable HCV viremia beyond 2 weeks post-transplantation, and all achieved sustained virologic response 12 weeks after therapy (SVR12). There were no study-related severe adverse events. One patient experienced early graft loss due to venous thrombosis, whereas the remaining 7 patients had excellent allograft function at 6 months. CONCLUSION: Preemptive elbasvir and grazoprevir eliminated HCV infection in HCV-naive patients who received a kidney transplant from an HCV-infected donor.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sise ME, Strohbehn IA, Chute DF, et al. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep. 2020. PMID: 32280841. doi:10.1016/j.ekir.2020.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。